Put a full name to the medicine.

Which medicine, in which form?

Ask for the full drug name. Then ask whether the product is ready-made or custom-made, and whether it is a tablet or an injection.

What names might come up?

These examples show why the full name matters.

• Semaglutide and tirzepatide are medicine ingredients. For type 2 diabetes, FDA approval covers semaglutide (Ozempic) and tirzepatide (Mounjaro) as of September 2026. For weight treatment, it covers Wegovy (semaglutide) and Zepbound (tirzepatide). Each product has its own limits on who it is for.
• BPC-157, ipamorelin and retatrutide are names of peptide substances. In September 2026, FDA records contained no approved US medicine with any of these names.
• Retatrutide is being studied for long-term weight treatment, as of September 2026. A study does not make it an approved treatment.
• If an offer links one of these substances to knee pain or weight, ask what evidence supports that exact claim. The recorded facts here do not describe advertised uses for the other substances.
• Cagrilintide is also an unapproved drug ingredient. As of September 2026, FDA says compounding with retatrutide or cagrilintide is barred by federal law. Compounding means making medicines to order.

Is custom-made the same as generic?

Compounded means made to order. A generic is an approved copy. Ask which kind the offer describes.

• In the US, neither semaglutide nor tirzepatide has an approved generic that may be marketed, as of September 2026.
• Generic liraglutide does have US approval, including products with a weight-management use, as of September 2026.
• A business described as “FDA registered” is on the FDA’s records, as of September 2026. An “NDC” number identifies a drug product in a government directory. Neither means the medicine has FDA approval.

What can you ask next?

Bring the exact wording of the offer to a visit.

• “Which exact product would this be?”
• “What use is it approved for, if any?”
• “Who makes it and who fills the prescription?”